Threonine for Liver Health and Lipid Metabolism

Threonine is one of the four classical lipotropic nutrients — choline, methionine, inositol, and threonine — the substances whose deficiency causes fat to accumulate in the liver. The connection between dietary threonine and hepatic steatosis was established in the 1930s and 1940s in elegant rat-feeding experiments by Best, Channon, and others, who showed that a threonine-deficient diet produced a fatty liver that could be reversed by adding back threonine, choline, or methionine interchangeably. The shared mechanism turned out to be one-carbon metabolism: threonine fed via glycine into the methionine cycle becomes a methyl-group donor for phosphatidylcholine synthesis, the surfactant phospholipid that the liver needs to package triglyceride into VLDL particles for export. Modern non-alcoholic fatty liver disease (NAFLD) is a different epidemiologic problem than 1940s rat-model fatty liver, but the underlying metabolic chemistry is the same, and threonine's lipotropic role remains experimentally robust. This page walks through the lipotrope chemistry, the methionine equivalence, the VLDL export pathway, the modern fatty-liver epidemic, and what threonine optimization can and cannot deliver clinically.

The Lipotrope Concept
Threonine Deficiency and Fatty Liver in Rats
The Methionine and Choline Equivalence
One-Carbon Metabolism and Methylation
VLDL Assembly and Lipid Export
Modern NAFLD — A Different Epidemic
Threonine to Glycine to Phosphatidylcholine
Threonine and Phase II Detoxification
Supplementation Evidence in Hepatic Steatosis
Clinical Applications
Cautions
Key Research Papers
Connections

The Lipotrope Concept

The term "lipotropic" was coined in the late 1930s to describe substances that prevent or reverse the accumulation of fat in the liver. The original four lipotropes identified in classical nutritional biochemistry were:

Choline — the founding lipotrope, identified by Best and colleagues in the 1930s after observing that choline deficiency in rats produced fatty liver within weeks
Methionine — the essential amino acid that serves as the body's primary methyl-group donor, identified as lipotropic in early 1940s studies
Inositol — the cyclic sugar alcohol that is a component of membrane phospholipids and intracellular signaling molecules
Threonine — identified as lipotropic in feeding experiments by Channon and colleagues in the 1940s, with subsequent confirmation by Brewer, Eagle, and Harris

The shared property of these four nutrients is that they all support, directly or indirectly, the synthesis of phosphatidylcholine in the liver. Phosphatidylcholine is the major phospholipid in cell membranes, but its specific relevance to fatty liver is that it is the essential surfactant phospholipid in the surface monolayer of VLDL (very low-density lipoprotein) particles — the lipid-transport vehicles that move triglyceride out of the liver into peripheral circulation. Without adequate phosphatidylcholine, VLDL cannot be assembled, triglyceride cannot be exported from the liver, and the result is accumulation of triglyceride droplets in hepatocytes — hepatic steatosis, or fatty liver.

Threonine's role in this network is indirect but real. Threonine feeds into glycine via threonine aldolase or via threonine dehydrogenase pathways. Glycine in turn participates in the folate-mediated one-carbon cycle that generates methyl groups for the methionine cycle. The methionine cycle generates S-adenosylmethionine (SAMe), which donates methyl groups to phosphatidylethanolamine to convert it to phosphatidylcholine via the PEMT (phosphatidylethanolamine N-methyltransferase) pathway. Threonine inadequacy at the top of this cascade ultimately reduces phosphatidylcholine availability at the bottom.

Back to Table of Contents

Threonine Deficiency and Fatty Liver in Rats

The classic feeding experiments demonstrating threonine's lipotropic action were performed in young rats in the 1940s through 1960s. The design was straightforward: feed weanling rats purified amino-acid-based diets with all essential amino acids except threonine, or with reduced threonine content, and measure hepatic lipid accumulation after 2-4 weeks.

Findings consistently included:

Threonine-deficient rats accumulated triglyceride in the liver, often reaching 15-25% of liver weight as lipid (vs. 4-6% in controls)
The fatty liver developed within 7-14 days of starting the deficient diet
Adding back threonine restored normal hepatic lipid content within 7-14 days
Adding choline or methionine to the threonine-deficient diet also reversed the fatty liver, confirming the lipotrope equivalence
Total serum cholesterol was often elevated in threonine-deficient rats, with reduced HDL fraction
Liver protein synthesis was reduced, but the lipid accumulation appeared even before frank protein synthesis suppression, suggesting a specific lipotropic effect distinct from generalized growth failure

The cleanest mechanistic interpretation, developed over multiple decades of follow-up work, is that threonine deficiency impaired phosphatidylcholine synthesis (via reduced one-carbon flux from threonine through glycine through the folate cycle to methionine and SAMe), which in turn impaired VLDL assembly and triglyceride export from the liver, producing accumulation. Adding choline or methionine bypassed the threonine-dependent steps in the same pathway by providing the methyl groups or the phosphatidylcholine substrate directly.

Rat models of fatty liver are an imperfect proxy for the modern human fatty liver epidemic (see the NAFLD section below), but the lipotropic chemistry that emerged from these studies remains valid and continues to inform clinical understanding of hepatic lipid metabolism.

Back to Table of Contents

The Methionine and Choline Equivalence

One of the most elegant findings from the classical lipotrope studies was the observation that threonine, methionine, and choline could substitute for each other to varying degrees in preventing fatty liver. The interchangeability is not complete — methionine cannot fully substitute for choline if the methionine intake exceeds the capacity of the methionine cycle, and threonine cannot substitute for methionine in protein synthesis — but for the specific endpoint of preventing hepatic triglyceride accumulation, the three nutrients act largely on the same final common pathway.

The metabolic explanation:

Choline is converted directly to phosphatidylcholine via the CDP-choline (Kennedy) pathway in hepatocytes, providing the essential VLDL surfactant lipid without requiring methylation steps
Methionine is converted to S-adenosylmethionine (SAMe), which donates methyl groups to phosphatidylethanolamine to convert it to phosphatidylcholine via the PEMT pathway (an alternative source of PC that does not depend on dietary choline)
Threonine indirectly supports both pathways. Via threonine dehydrogenase, threonine yields aminoacetone and acetyl-CoA; via threonine aldolase (less prominent in adult human liver but present), threonine yields glycine and acetaldehyde. The glycine generated from threonine feeds into the folate one-carbon cycle and ultimately regenerates methionine from homocysteine, supporting SAMe production and the PEMT pathway.

This three-way redundancy is why classical nutrition emphasizes the "lipotropic factors" collectively rather than emphasizing any one of them in isolation. Choline is now generally considered the master lipotrope (because it most directly provides phosphatidylcholine without requiring intermediate methylation), but threonine and methionine each contribute to the redundant supply chain.

The clinical implication for modern patients is that fatty liver is rarely the result of inadequate intake of any single one of these nutrients in isolation. A diet adequate in protein and containing eggs, fish, organ meats, or soy products will provide adequate choline, methionine, and threonine simultaneously. The patients most at risk for lipotrope inadequacy are those on restrictive diets (low total protein, very low fat, low animal product) without explicit attention to choline-rich foods, or those with malabsorption.

For more on related lipotropic nutrients, see our pages on Methionine and any choline / lecithin content on the site.

Back to Table of Contents

One-Carbon Metabolism and Methylation

One-carbon metabolism is the network of biochemical reactions that transfer single-carbon units (methyl groups and related fragments) between molecules in the cell. It is one of the most quantitatively important metabolic systems in the human body and is essential for DNA synthesis (purine and thymidine), protein methylation, phospholipid methylation, and neurotransmitter synthesis.

The central currency of one-carbon metabolism is the methyl group attached to S-adenosylmethionine (SAMe), the universal methyl donor. SAMe donates methyl groups to dozens of acceptor molecules — including DNA, histones, neurotransmitters, and phosphatidylethanolamine — producing S-adenosylhomocysteine (SAH) as the byproduct. SAH is hydrolyzed to homocysteine, which can either be remethylated back to methionine (using either 5-methyltetrahydrofolate from the folate cycle, or methyl groups donated by trimethylglycine/betaine) or shunted to cystathionine and ultimately to cysteine via the transsulfuration pathway.

Threonine intersects this network at the glycine node. Two routes from threonine to glycine exist:

Threonine dehydrogenase (TDH) pathway — the dominant adult human catabolic route. Threonine is oxidized to 2-amino-3-ketobutyrate, which is cleaved to glycine and acetyl-CoA by 2-amino-3-ketobutyrate coenzyme A ligase. (Note: there is ongoing scientific debate about how active TDH is in adult humans; some studies suggest the enzyme is largely a pseudogene in humans and that other catabolic routes dominate.)
Threonine aldolase pathway — direct cleavage of threonine to glycine and acetaldehyde. This pathway is more prominent in some species and developmental stages than in adult humans.

Glycine then participates in one-carbon metabolism via the glycine cleavage system (GCS), which generates 5,10-methylenetetrahydrofolate — the activated one-carbon unit that feeds into thymidine synthesis (for DNA) and into 5-methyltetrahydrofolate (for methionine regeneration from homocysteine, hence supporting SAMe and the entire methylation network including phosphatidylcholine production).

The connection between threonine and phosphatidylcholine is therefore real but is indirect, with multiple metabolic intermediates between threonine intake and phosphatidylcholine synthesis. In practice, total dietary glycine status, folate status, vitamin B12 status, and choline intake are usually more direct determinants of methylation capacity than threonine intake alone. But threonine adequacy contributes to the overall glycine pool, and the lipotropic effect is real and reproducible in controlled feeding studies.

Back to Table of Contents

VLDL Assembly and Lipid Export

The mechanism by which the liver exports triglyceride to the rest of the body is the assembly and secretion of VLDL (very low-density lipoprotein) particles. VLDL particles are spherical structures with a hydrophobic core (triglyceride and cholesteryl ester) surrounded by a surface monolayer of phospholipids, free cholesterol, and apolipoproteins (primarily ApoB-100 in human VLDL).

The phospholipid most enriched in the VLDL surface monolayer is phosphatidylcholine (PC), which accounts for approximately 65-75% of the surface phospholipid. PC is uniquely suited for this role because of its zwitterionic head group geometry, which forms stable monolayer interfaces with hydrophobic lipid cores. Other phospholipids (phosphatidylethanolamine, phosphatidylserine, sphingomyelin) cannot substitute structurally for PC in the VLDL surface monolayer to the same degree.

The liver synthesizes phosphatidylcholine through two parallel pathways:

The CDP-choline (Kennedy) pathway — uses dietary choline (or recycled choline from membrane turnover) to produce PC directly. This is the major PC production route in most tissues.
The PEMT (phosphatidylethanolamine N-methyltransferase) pathway — converts phosphatidylethanolamine to PC by adding three methyl groups donated by SAMe. This pathway is significant only in the liver (PEMT expression is largely liver-restricted) and accounts for approximately 30% of hepatic PC production under normal conditions, with the proportion increasing when dietary choline is limited.

The PEMT pathway is the link to the lipotrope chemistry. When dietary choline is low, the liver must compensate by relying more heavily on PEMT to maintain PC supply for VLDL. PEMT in turn depends on SAMe, which depends on methionine, which depends on the entire one-carbon metabolism network including threonine's indirect contribution. Inadequate threonine (or methionine, or folate, or B12) reduces PEMT capacity, reduces PC supply, reduces VLDL assembly, and produces hepatic triglyceride accumulation.

This is the mechanistic chain that explains why all the classical lipotropes — choline, methionine, threonine, and inositol — converge on the same clinical endpoint (fatty liver). They all support the production of the surfactant phospholipid required for triglyceride export, with choline acting most directly and the others acting through the methionine cycle.

Back to Table of Contents

Modern NAFLD — A Different Epidemic

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver condition worldwide, with prevalence estimated at 25-30% of the adult population in industrialized countries. NAFLD is associated with obesity, insulin resistance, type 2 diabetes, dyslipidemia, and metabolic syndrome. It is the leading cause of end-stage liver disease projected for the 2030s and is now a leading indication for liver transplantation in the United States.

NAFLD is mechanistically different from the classical lipotrope-deficient fatty liver of mid-20th-century animal models in important ways:

The dominant driver of modern NAFLD is excess caloric and carbohydrate intake (especially fructose) that overwhelms the liver's capacity to package and export triglyceride at the rate of new triglyceride production. The problem is not insufficient export machinery (lipotrope-deficiency fatty liver) but excess incoming substrate (overload fatty liver).
Insulin resistance amplifies the problem by directing more peripheral free fatty acids back to the liver while simultaneously increasing hepatic de novo lipogenesis
The progression from simple steatosis to steatohepatitis (NASH) involves inflammation, oxidative stress, and lipotoxicity from specific lipid species — mechanisms that are not directly addressed by lipotropic nutrient supplementation

That said, lipotrope status does still matter in modern NAFLD:

Choline inadequacy is common — the Institute of Medicine's AI for choline is 425 mg/day for women and 550 mg/day for men, and most Americans consume less than this. Patients with NAFLD often have suboptimal choline intake, which can amplify fatty liver severity.
Genetic variation in PEMT matters — the rs7946 polymorphism in the PEMT gene reduces PEMT activity in some individuals, making them more dependent on dietary choline and more vulnerable to lipotrope inadequacy. These individuals develop fatty liver more readily on low-choline diets.
Methionine and folate status contribute to PEMT activity through the SAMe pathway. B12 and folate inadequacy can compound lipotrope inadequacy.
Threonine's role in modern NAFLD is less directly studied than choline or methionine, but the same biochemistry applies. Patients with marginal threonine intake (very low total protein diets, restrictive vegan diets, IBD) may have an additional contributor to lipotrope inadequacy.

For more on NAFLD management, see our Non-Alcoholic Fatty Liver Disease page if available, and related metabolic-syndrome and insulin-resistance content.

Back to Table of Contents

Threonine to Glycine to Phosphatidylcholine

The connection from threonine to phosphatidylcholine production runs through glycine, which deserves its own moment of attention. Glycine is technically a non-essential amino acid in adult humans, meaning that the body can synthesize it from other precursors (serine, threonine, choline, and others). However, several lines of evidence suggest that glycine is conditionally essential — that endogenous glycine synthesis often does not keep pace with metabolic demand, and dietary supplementation of glycine has measurable health effects.

Estimated daily glycine flux through human metabolism is approximately 14-15 grams per day, dwarfing dietary intake of glycine (typically 3-5 g/day in mixed diets). The gap is filled by endogenous synthesis from serine and threonine. If threonine intake is inadequate, the threonine-to-glycine arm of this synthesis collapses, and the entire glycine pool becomes more dependent on the serine-to-glycine arm and on the limited dietary glycine intake. Net result: lower glycine availability for the multiple metabolic demands that include one-carbon metabolism, collagen synthesis (glycine is one-third of every collagen molecule), and bile acid conjugation.

Glycine's contribution to one-carbon metabolism and methylation is particularly relevant for the lipotropic effect. The glycine cleavage system in mitochondria oxidizes glycine to CO₂ and ammonia while donating a one-carbon unit to tetrahydrofolate, generating 5,10-methylenetetrahydrofolate. This is one of the major routes by which the folate one-carbon pool is loaded with methyl groups that ultimately support methionine regeneration and SAMe production.

The therapeutic implication is that for fatty liver patients with marginal lipotrope status, addressing the entire choline-methionine-folate-B12-glycine-threonine network is more effective than focusing on any single nutrient. A modest threonine deficit alongside a modest choline deficit alongside marginal folate status can compound into clinically significant lipotrope inadequacy that no single supplement fully corrects. For more on glycine, see our Glycine page.

Back to Table of Contents

Threonine and Phase II Detoxification

Beyond the lipotropic role, threonine contributes to liver function through its metabolic conversion to glycine, which is a major substrate for phase II detoxification. The liver disposes of fat-soluble toxins, drug metabolites, and endogenous waste molecules by conjugating them to small water-soluble molecules and excreting the conjugates in bile or urine.

Glycine conjugation handles several classes of substrate:

Bile acids — cholic acid and chenodeoxycholic acid are conjugated with glycine (about 75% of human bile acids) or taurine (about 25%) to form the bile salts that emulsify dietary fat. Adequate glycine supply is required to maintain the bile acid pool.
Benzoate and related aromatic acids — conjugated with glycine to form hippurate, which is excreted in urine. This is the disposal pathway for sodium benzoate (a common food preservative) and for benzoate produced from gut bacterial metabolism of dietary aromatic compounds.
Salicylate — aspirin metabolism includes glycine conjugation as one of several routes
Various other xenobiotic carboxylic acids

Inadequate glycine supply can constrain the rate of glycine conjugation when detoxification demand is high, leading to accumulation of unconjugated parent compounds or shunting to alternative (and sometimes more toxic) metabolic routes. The clinical relevance is most acute in patients with severe liver disease, chronic exposure to high glycine-conjugation-demand drugs (high-dose aspirin), or chronic exposure to environmental compounds requiring glycine conjugation.

Threonine, via its contribution to the glycine pool, supports this detoxification capacity indirectly. In most well-nourished patients, the contribution is too small to be clinically obvious, but in patients with marginal protein status it can compound the overall reduction in detoxification capacity.

Back to Table of Contents

Supplementation Evidence in Hepatic Steatosis

The evidence base for isolated threonine supplementation in human hepatic steatosis is limited. Most studies have been done in animal models or in combination supplementation protocols. Highlights:

Animal studies consistently show that adding threonine to a lipotrope-deficient diet reverses fatty liver. This is the foundational evidence and is uncontroversial.
Choline supplementation in humans with NAFLD has been studied more extensively than threonine and shows modest improvement in some studies but mixed results overall. Choline-rich diet is generally recommended as part of NAFLD nutritional management.
SAMe supplementation in alcoholic liver disease has shown benefit in some trials, supporting the broader principle that supporting methylation capacity helps liver function
Combination amino acid formulas — some commercial "liver support" supplements combine threonine with methionine, choline, inositol, and other compounds. The evidence base for any specific combination formula is generally weak.
Branched-chain amino acid (BCAA) supplementation — in advanced cirrhosis, BCAA supplementation has stronger evidence (multiple RCTs) for improving outcomes, but this is a different clinical context (sarcopenia and hepatic encephalopathy in cirrhosis) than fatty liver per se

The pragmatic clinical approach for NAFLD nutritional management:

Caloric restriction and weight loss are the most-evidence-based intervention. 5-10% body weight loss reliably reduces hepatic steatosis.
Reduce fructose and refined carbohydrate intake (major drivers of de novo lipogenesis in the liver)
Increase choline-rich foods (eggs, liver, fish, soy)
Ensure adequate total protein (1.0-1.2 g/kg/day) from high-biological-value sources, which provides all the lipotropic amino acids including threonine
Address co-existing micronutrient deficiencies (vitamin D, vitamin E, B12, folate)
Consider Mediterranean diet pattern, which has the strongest dietary-pattern evidence for NAFLD improvement

Standalone L-threonine supplementation for fatty liver is not commonly recommended and lacks supporting evidence in humans. If used, typical doses would be 500-1,000 mg/day in divided doses, but the more impactful interventions are listed above.

Back to Table of Contents

Clinical Applications

The clinical situations where threonine's lipotropic role becomes practically relevant include:

NAFLD with concurrent malnutrition or restrictive diet — patients with NAFLD who also have inadequate total protein intake, very low choline intake, or restrictive vegan diets without adequate plant protein combining may have a meaningful lipotrope inadequacy contributing to their liver disease. Optimize total protein intake and choline-rich foods.
Long-term parenteral nutrition — PN-associated liver disease is partly driven by lipotrope inadequacy in standard amino acid formulas. Modern PN formulations include choline and adequate threonine to address this.
Bariatric surgery patients — reduced food intake and altered fat absorption can compromise lipotrope status. Routine multivitamin and adequate protein intake usually suffices.
Inflammatory bowel disease with documented hepatic steatosis — the combination of malabsorption, reduced intake, and increased gut threonine demand can produce both intestinal and hepatic complications. Comprehensive nutritional support.
Cystic fibrosis — pancreatic insufficiency, fat malabsorption, and elevated metabolic demand all converge on lipotrope inadequacy. CF-associated liver disease has multifactorial nutritional contributors.
Alcoholic liver disease — SAMe depletion is a well-established mechanism. Threonine's role is less direct, but supporting the entire methylation network is part of comprehensive nutritional therapy.

For most patients with NAFLD, the dominant therapeutic interventions are weight loss, reduced fructose and refined carbohydrate intake, and treatment of underlying insulin resistance. Lipotrope optimization (choline-rich foods, adequate protein, attention to B vitamins) is supportive but not curative.

Back to Table of Contents

Cautions

Hepatic steatosis is multifactorial. Insulin resistance, fructose intake, and excess caloric intake drive modern NAFLD far more than any individual nutrient inadequacy. Lipotrope optimization without addressing the underlying metabolic problem will not resolve fatty liver.
Advanced liver disease requires specialist management. Threonine supplementation should not substitute for hepatology evaluation and management of any advanced liver condition.
Excessive methionine — while methionine is a primary lipotrope, sustained high-dose methionine supplementation can elevate homocysteine (a cardiovascular risk factor) and is not recommended as a long-term strategy. Threonine does not directly raise homocysteine.
Choline overload — very high doses of choline (above 3 g/day) can produce a fishy body odor (trimethylaminuria) and gastrointestinal upset. The Tolerable Upper Intake Level is 3.5 g/day for adults.
Renal impairment — isolated amino acid supplementation should be avoided in advanced CKD without nephrology guidance.
The threonine-glycine pathway in adult humans is debated. Some recent literature suggests that the TDH (threonine dehydrogenase) enzyme is largely a pseudogene in adult humans, with most threonine catabolism proceeding via threonine dehydratase to alpha-ketobutyrate. If TDH is not active, the contribution of threonine to glycine supply is smaller than the rat-model literature suggests, and the lipotropic effect of threonine in adult humans may be more modest than in rats. The clinical relevance of this is not yet fully resolved.

Back to Table of Contents

Key Research Papers

Best CH, Huntsman ME (1932). The effects of the components of lecithine upon deposition of fat in the liver. Journal of Physiology. (Foundational lipotrope work.) — PubMed
Channon HJ, Manifold MC, Platt AP (1938). The action of various substances on the fatty livers produced in rats by a diet rich in cholesterol. Biochemical Journal. — PubMed
du Vigneaud V et al. (1945). The role of choline and methionine in fat metabolism. Annual Review of Biochemistry. — PubMed
Vance DE, Vance JE (2008). Phospholipid biosynthesis in mammalian cells. Biochemistry and Cell Biology. — PubMed
Vance DE (2014). Phospholipid methylation in mammals: from biochemistry to physiological function. Biochimica et Biophysica Acta. — PubMed
Zeisel SH, da Costa KA (2009). Choline: an essential nutrient for public health. Nutrition Reviews. — PubMed
Corbin KD, Zeisel SH (2012). Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Current Opinion in Gastroenterology. — PubMed
Edgar AJ (2002). The human L-threonine 3-dehydrogenase gene is an expressed pseudogene. BMC Genetics. (Evidence that TDH may be inactive in adult humans.) — PubMed
Wang W et al. (2013). Glycine metabolism in animals and humans: implications for nutrition and health. Amino Acids. — PubMed
Anstee QM, Goldin RD (2006). Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. International Journal of Experimental Pathology. — PubMed
Niculescu MD, Zeisel SH (2002). Diet, methyl donors and DNA methylation: interactions between dietary folate, methionine and choline. Journal of Nutrition. — PubMed
Vance DE et al. (2007). Hepatic phosphatidylethanolamine N-methyltransferase, unexpected roles in animal biochemistry and physiology. Journal of Biological Chemistry. — PubMed
Hayashi H et al. (2000). Phosphatidylcholine deficiency in liver causes fatty liver and reduces VLDL secretion. Lipids. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents